Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Capital Expenditures (2016 - 2019)

Alterity Therapeutics' quarterly Capital Expenditures came in at -$5123.2 in Q4 2019, down 118.19% year-on-year from $28162.0 in Q4 2018, and down 118.19% quarter-over-quarter from -$2348.0 in Q4 2018.

Alterity Therapeutics has reported Capital Expenditures for 4 years, with the latest figure at -$5123.2 in Q4 2019.

  • For the quarter ending Q4 2019, Capital Expenditures fell 118.19% year-over-year to -$5123.2; the trailing twelve-month figure through Dec 2019 stood at -$26661.1 (changed N/A YoY), and the FY2024 full-year result was -$5722.0, changed N/A from the prior year.
  • Capital Expenditures for Q4 2019 stood at -$5123.2, down from -$2348.0 in the prior quarter.
  • The five-year high for Capital Expenditures was -$2348.0 in Q4 2018, with the low at -$16622.8 in Q4 2016.
  • Average Capital Expenditures over 4 years is -$6665.3, with a median of -$3845.1 recorded in 2017.
  • Year-over-year, Capital Expenditures jumped 84.56% in 2017 and sank 118.19% in 2019.
  • Tracing ATHE's Capital Expenditures over 4 years: stood at -$16622.8 in 2016, then jumped by 84.56% to -$2567.1 in 2017, then advanced by 8.53% to -$2348.0 in 2018, then plunged by 118.19% to -$5123.2 in 2019.
  • The last three Capital Expenditures figures came in at -$5123.2 (Q4 2019), -$2348.0 (Q4 2018), and -$2567.1 (Q4 2017), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 133.40 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 230.60 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 21.83 Mn
10 Revolution Medicines 32.39 Bn 32.39 Bn - 786,000.00

Historic Data

Download Data 🔒
DateValue
Dec 31, 2019 -5,123.23
Dec 31, 2019 -5,123.23
Dec 31, 2018 -2,348.04
Dec 31, 2018 -2,348.04
Dec 31, 2017 -2,567.05
Dec 31, 2017 -2,567.05
Dec 31, 2016 -16,622.76
Dec 31, 2016 -16,622.76